These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 16412636)

  • 21. Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines.
    Hubbard RD; Dickerson SH; Emerson HK; Griffin RJ; Reno MJ; Hornberger KR; Rusnak DW; Wood ER; Uehling DE; Waterson AG
    Bioorg Med Chem Lett; 2008 Nov; 18(21):5738-40. PubMed ID: 18842405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
    Xu G; Searle LL; Hughes TV; Beck AK; Connolly PJ; Abad MC; Neeper MP; Struble GT; Springer BA; Emanuel SL; Gruninger RH; Pandey N; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA; Greenberger LM
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3495-9. PubMed ID: 18508264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis, biological evaluation and molecular docking studies of amide-coupled benzoic nitrogen mustard derivatives as potential antitumor agents.
    Zheng QZ; Zhang F; Cheng K; Yang Y; Chen Y; Qian Y; Zhang HJ; Li HQ; Zhou CF; An SQ; Jiao QC; Zhu HL
    Bioorg Med Chem; 2010 Jan; 18(2):880-6. PubMed ID: 20005116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor.
    Pawar VG; Sos ML; Rode HB; Rabiller M; Heynck S; van Otterlo WA; Thomas RK; Rauh D
    J Med Chem; 2010 Apr; 53(7):2892-901. PubMed ID: 20222733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.
    Tsou HR; Overbeek-Klumpers EG; Hallett WA; Reich MF; Floyd MB; Johnson BD; Michalak RS; Nilakantan R; Discafani C; Golas J; Rabindran SK; Shen R; Shi X; Wang YF; Upeslacis J; Wissner A
    J Med Chem; 2005 Feb; 48(4):1107-31. PubMed ID: 15715478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and biological evaluation of novel 2,4'-bis substituted diphenylamines as anticancer agents and potential epidermal growth factor receptor tyrosine kinase inhibitors.
    Abou-Seri SM
    Eur J Med Chem; 2010 Sep; 45(9):4113-21. PubMed ID: 20580136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents.
    Steiner L; Blum G; Friedmann Y; Levitzki A
    Eur J Pharmacol; 2007 May; 562(1-2):1-11. PubMed ID: 17376430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2).
    Wissner A; Overbeek E; Reich MF; Floyd MB; Johnson BD; Mamuya N; Rosfjord EC; Discafani C; Davis R; Shi X; Rabindran SK; Gruber BC; Ye F; Hallett WA; Nilakantan R; Shen R; Wang YF; Greenberger LM; Tsou HR
    J Med Chem; 2003 Jan; 46(1):49-63. PubMed ID: 12502359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of 2-anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation.
    Egert-Schmidt AM; Dreher J; Dunkel U; Kohfeld S; Preu L; Weber H; Ehlert JE; Mutschler B; Totzke F; Schächtele C; Kubbutat MH; Baumann K; Kunick C
    J Med Chem; 2010 Mar; 53(6):2433-42. PubMed ID: 20170163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor.
    Liechti C; Séquin U; Bold G; Furet P; Meyer T; Traxler P
    Eur J Med Chem; 2004 Jan; 39(1):11-26. PubMed ID: 14987830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones.
    Traxler P; Green J; Mett H; Séquin U; Furet P
    J Med Chem; 1999 Mar; 42(6):1018-26. PubMed ID: 10090785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
    Li Q; Li T; Zhu GD; Gong J; Claibone A; Dalton C; Luo Y; Johnson EF; Shi Y; Liu X; Klinghofer V; Bauch JL; Marsh KC; Bouska JJ; Arries S; De Jong R; Oltersdorf T; Stoll VS; Jakob CG; Rosenberg SH; Giranda VL
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1679-85. PubMed ID: 16403626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Daphnetin, one of coumarin derivatives, is a protein kinase inhibitor.
    Yang EB; Zhao YN; Zhang K; Mack P
    Biochem Biophys Res Commun; 1999 Jul; 260(3):682-5. PubMed ID: 10403826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and synthesis of a series of novel bisquinazoline glycosides as epidermal growth factor receptor inhibitors.
    Chen S; Zhang X; Wang J; Wan S; Geng M; Jiang T
    Chem Biol Drug Des; 2011 Dec; 78(6):1006-13. PubMed ID: 21824331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and characterization of N9/N7-substituted 6-aminopurines as VEGF-R and EGF-R inhibitors.
    Peifer C; Bühler S; Hauser D; Kinkel K; Totzke F; Schächtele C; Laufer S
    Eur J Med Chem; 2009 Apr; 44(4):1788-93. PubMed ID: 18524423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and biological evaluation of benzamides and benzamidines as selective inhibitors of VEGFR tyrosine kinases.
    Nakamura H; Sasaki Y; Uno M; Yoshikawa T; Asano T; Ban HS; Fukazawa H; Shibuya M; Uehara Y
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5127-31. PubMed ID: 16893647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allene as an alternative functional group for drug design: effect of C--C multiple bonds conjugated with quinazolines on the inhibition of EGFR tyrosine kinase.
    Ban HS; Onagi S; Uno M; Nabeyama W; Nakamura H
    ChemMedChem; 2008 Jul; 3(7):1094-103. PubMed ID: 18465761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A cell-based high-throughput screen for epidermal growth factor receptor pathway inhibitors.
    Lin WH; Song JS; Chang TY; Chang CY; Fu YN; Yeh CL; Wu SH; Huang YW; Fang MY; Lien TW; Hsieh HP; Chao YS; Huang SF; Tsai SF; Wang LM; Hsu JT; Chen YR
    Anal Biochem; 2008 Jun; 377(1):89-94. PubMed ID: 18358823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases.
    Mastalerz H; Chang M; Gavai A; Johnson W; Langley D; Lee FY; Marathe P; Mathur A; Oppenheimer S; Tarrant J; Tokarski JS; Vite GD; Vyas DM; Wong H; Wong TW; Zhang H; Zhang G
    Bioorg Med Chem Lett; 2007 May; 17(10):2828-33. PubMed ID: 17368025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases.
    Fidanze SD; Erickson SA; Wang GT; Mantei R; Clark RF; Sorensen BK; Bamaung NY; Kovar P; Johnson EF; Swinger KK; Stewart KD; Zhang Q; Tucker LA; Pappano WN; Wilsbacher JL; Wang J; Sheppard GS; Bell RL; Davidsen SK; Hubbard RD
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2452-5. PubMed ID: 20346655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.